OneSource Specialty Pharma Limited announced its unaudited standalone and consolidated financial results for the quarter ended December 31, 2025. The company reported a consolidated total income of ₹2,949.65 million. The standalone profit/loss after tax stood at ₹(621.85) million. Key strategic initiatives, including a composite scheme of arrangement, are progressing, aiming to enhance operational efficiencies and financial restructuring.
Financial Performance Overview
OneSource Specialty Pharma Limited has released its unaudited financial results for the quarter that concluded on December 31, 2025. Key highlights from the consolidated results include:
- Total Income: ₹2,949.65 million
- Profit/Loss before tax: ₹(930.11) million
- Profit/Loss after tax: ₹(886.99) million
The standalone results reflect:
- Total Income: ₹2,948.44 million
- Profit/Loss before tax: ₹(621.85) million
- Profit/Loss after tax: ₹(621.85) million
Expenses and Operational Factors
The consolidated expenses for the quarter encompassed various categories, including:
- Cost of materials consumed: ₹489.16 million
- Employee benefits expenses: ₹641.92 million
- Finance costs: ₹382.31 million
Strategic Initiatives
OneSource is actively pursuing a composite scheme of arrangement and amalgamation aimed at streamlining operations and improving financial health. This scheme involves several entities and is currently awaiting regulatory approvals. This move is expected to enhance the company’s financial stability by setting off negative balances against the securities premium account.
Other Key Points
- Earnings per share (EPS) from continuing operations stood at ₹(7.74).
These results are part of OneSource’s ongoing efforts to navigate market challenges and optimize its business structure for sustainable growth.
Source: BSE
